SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more

 We are pausing publication of The Daily Briefing out of respect for the tragic passing of Brian Thompson. We will resume publication of this daily newsletter in the coming days.

Daily Briefing

New XEC variant is 'just getting started.' Will it cause a COVID-19 surge?


A new subvariant of the coronavirus, called XEC, is picking up steam in Europe and starting to draw attention as a potential threat for COVID-19 surges in the United States this fall and winter. But experts say current vaccines should still offer protection.

What is XEC?

XEC is a subvariant of the omicron family and a hybrid between two previously documented subvariants: KP.3 and KS.1.1.

"XEC represents a fairly minor evolution relative to the SARS-CoV-2 diversity currently in circulation, and is not a highly derived novel variant such as those that were granted Greek letters," like alpha, delta, and omicron, said Francois Balloux, a computational biologist at University College London and director of the UCL Genetics Institute.

The new subvariant was first detected in Germany and is currently spreading through Western Europe, said Elizabeth Hudson, regional chief of infectious diseases at Kaiser Permanente Southern California. According to Peter Chin-Hong, an infectious disease expert at the University of California, San Francisco, XEC may make up 13% of coronavirus samples in Germany and 7% of samples in Britain.

XEC has yet to spread much in the United States. According to CDC, KP.3.1.1, a descendant of the FLiRT subvariants, is currently the dominant strain of the coronavirus nationwide. For the two-week period ending in Sept. 14, KP.3.1.1 was estimated to comprise 52.7% of all coronavirus specimens.

By comparison, XEC isn't yet tracked on CDC's variant website and won't be until it makes up an estimated 1% or more of coronavirus cases nationwide by CDC's estimates. However, another estimate from the variant tracker GISAID indicates that XEC currently makes up 1.11% of coronavirus cases in the United States as of Sept. 15.

Could XEC cause a fall and winter surge?

Some experts say it's likely that XEC will eventually become the dominant variant in the United States.

According to Hudson, past surges have tended "to move from Western Europe to the East Coast to the West Coast of the U.S. So if this does take off more and more as we get towards the colder weather months, this probably would be the variant that will potentially take hold."

Eric Topol, director of the Scripps Research Translational Institute, said that XEC is "just getting started."

"And that's going to take many weeks, a couple months, before it really takes hold and starts to cause a wave," Topol said. "XEC is definitely taking charge. That does appear to be the next variant. But it's months off from getting into high levels."

Hudson agreed, saying that if XEC does take off, "probably we should start to see it more like November, December time. So like after Halloween — when the weather will probably get more reliably cool here, people start to go indoors more often — that's when we're more likely to see this potentially take hold."

However, experts noted that current COVID-19 vaccines, which are formulated to target similar variants, should still offer protection against XEC.

Balloux said that while XEC has a "slight transmission advantage" over other recent coronavirus variants, vaccines should still offer good protection.

XEC is a "recombinant variant of some of the other Omicron lineages that have been around for a while, and it does appear to be more immune evasive, giving it a transmissibility advantage in the population with the immunity that it has," said Amesh Adalja, from the Johns Hopkins Center for Health Security. "But it doesn't really change anything, just like the last variant didn't change anything, or the one before that, one before that, or the one before that."

"If this becomes a dominant variant, it will decrease the efficacy against infection of the updated vaccines, but the updated vaccines will still be durable against severe disease [and] hospitalization, and that's what is really the primary function of our current, first-generation COVID vaccines," Adalja added.

"I always have hope," Hudson said. "And if folks get vaccinated — this is the perfect time now to get vaccinated against flu, get the new COVID shot — we could potentially tamp down on what will certainly be another more typical fall-and-winter surge. But I think the jury is out in terms of how bad it is going to be." (Lin, Los Angeles Times, 9/23; Lee, Forbes, 9/17; Roberts, BBC, 9/18; Putka, MedPage Today, 9/18)


Your top resources for Covid-19 readiness

Use our resource library to learn how health plans can manage the impact of COVID-19 and what to prepare for next.


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.